Wolcott-Rallison Syndrome: clinical, genetic and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity

Research output: Contribution to journalArticle

Authors

  • V Senee
  • KM Vattem
  • M Delepine
  • C Haton
  • A Lecoq
  • Nicholas Shaw
  • JJ Robert
  • R Rooman
  • C Diatloff-Zito
  • JL Michaud
  • B Bin-Abbas
  • D Taha
  • B Zabel
  • P Franceschini
  • AK Topaloglu
  • GM Lathrop
  • M Nicolino
  • RC Wek
  • C Julier

Colleges, School and Institutes

Abstract

Wolcott-Rallison syndrome (WRS) is a rare autosomal-recessive disorder characterized by the association of permanent neonatal or early-infancy insulin-dependent diabetes, multiple epiphyseal dysplasia and growth retardation, and other variable multisystemic clinical manifestations. Based on genetic studies of two inbred families, we previously identified the gene responsible for this disorder as EIF2AK3, the pancreatic eukaryotic initiation factor 2alpha (eIF2alpha) kinase. Here, we have studied 12 families with WRS, totalling 18 cases. With the exception of one case, all patients carried EIF2AK3 mutations resulting in truncated or missense versions of the protein. Exclusion of EIF2AK3 mutations in the one patient case was confirmed by both linkage and sequence data. The activities of missense versions of EIF2AK3 were characterized in vivo and in vitro and found to have a complete lack of activity in four mutant proteins and residual kinase activity in one. Remarkably, the onset of diabetes was relatively late (30 months) in the patient expressing the partially defective EIF2AK3 mutant and in the patient with no EIF2AK3 involvement (18 months) compared with other patients (

Details

Original languageEnglish
Pages (from-to)1876-1883
Number of pages8
JournalDiabetes
Volume53
Issue number7
Publication statusPublished - 1 Jul 2004